Retevmo® (selpercatinib)
for Lung Cancer

Retevmo (selpercatinib) is an oral kinase inhibitor used to treat cancers caused by abnormal RET genes. It is approved for locally advanced or metastatic NSCLC in adults, advanced or metastatic thyroid cancer in adults and children 2+, and advanced medullary thyroid cancer (MTC) in adults and children 2+. It is also approved for RET-altered solid tumors in patients 2+ when other treatments have failed. Retevmo blocks RET signals that cause cancer growth.

Heart